Zhejiang Hisun Pharmaceutical Co., Ltd.

Equities

600267

CNE0000013Z2

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-07-11 pm EDT 5-day change 1st Jan Change
7.2 CNY +0.14% Intraday chart for Zhejiang Hisun Pharmaceutical Co., Ltd. +0.84% -23.08%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Hisun Pharmaceutical's Veterinary Arm Gets Registration Certificate for Mirtazapine Ointment MT
Hisun Pharmaceutical's Leukemia Drug Passes Chinese Drug Regulator's Consistency Evaluation MT
Hisun Pharmaceutical's Leukemia Drug Gets Marketing Approval MT
Hisun Pharmaceutical Unit's Cladribine Injection Passes Regulatory Evaluation MT
Hisun Pharmaceutical's Veterinary Arm Gets Nod to Produce Fenbendazole Oral Suspension MT
Hisun Pharma's Veterinary Arm Gets Approval to Register Amoxicillin and Clavulanate Potassium Dry Suspension MT
Hisun Pharma's Veterinary Arm Gets Nod to Market Selamectin Drops MT
Zhejiang Hisun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Zhejiang Hisun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 23, 2023. CI
Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback announced on December 23, 2023, has closed with 11,687,200 shares, representing 0.98% for CNY 98.99 million. CI
Hisun Pharma's Unit Gets Nod for Pig Vaccine MT
Tranche Update on Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 23, 2023. CI
China Energy Engineering Issues Apology Over Former Director's Stake Disposal Breaches MT
Tranche Update on Zhejiang Hisun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 23, 2023. CI
Zhejiang Hisun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares. CI
Zhejiang Hisun Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Gogox Holdings Chairman Steps Down MT
Hisun Pharmaceutical's Unit Gets Certification for Imported Drug from Pfizer MT
Hisun Pharmaceutical CFO Resigns MT
Hisun Pharmaceutical's Unit Gets Import Drug Certificate for Methylprednisolone Tablets MT
Hisun Pharmaceutical's Unit Gets Nod for Carprofen Tablets for Dogs MT
Hisun Pharma Registers New Veterinary Drug MT
Zhejiang Hisun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hisun Pharmaceutical Gets China Nod to Market Cytarabine MT
Chart Zhejiang Hisun Pharmaceutical Co., Ltd.
More charts
Zhejiang Hisun Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the research and development, manufacture and distribution of specialty bulk pharmaceutical chemicals and preparation products. The Company's bulk pharmaceutical chemicals mainly include antineoplastic drugs, cardiovascular drugs, anti-infection drugs, endocrine control drugs, anthelmintic, as well as animal remedies, among others. The Company is also engaged in the sales of drugs manufactured by other companies. The Company distributes its products in domestic markets and to overseas markets.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
7.2 CNY
Average target price
7 CNY
Spread / Average Target
-2.78%
Consensus
  1. Stock Market
  2. Equities
  3. 600267 Stock
  4. News Zhejiang Hisun Pharmaceutical Co., Ltd.
  5. Hisun Pharmaceutical Unit's Cladribine Injection Passes Regulatory Evaluation